Bio-Rad Laboratories (BIO) Common Equity (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Common Equity data on file, last reported at $6.9 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 2.57% year-over-year to $6.9 billion in Q1 2026; TTM through Mar 2026 was $6.9 billion, a 2.57% increase from a year earlier, with the FY2025 full-year figure at $7.5 billion, up 13.46% from the prior year.
• Common Equity for Q1 2026 stood at $6.9 billion, down from $7.5 billion in the prior quarter.
• Over the last five years, Common Equity for BIO reached as high as $10.2 billion in Q1 2022 and fell as low as $97.2 million in Q2 2025.
• Historically, Common Equity has averaged $7.7 billion across 5 years, with a median of $8.4 billion in 2023.
• On a YoY basis, Common Equity climbed as much as 13.46% in 2025 and fell as far as 98.57% in 2025.
• Year by year, Common Equity stood at $9.6 billion in 2022, then declined by 9.09% to $8.7 billion in 2023, then dropped by 24.85% to $6.6 billion in 2024, then increased by 13.46% to $7.5 billion in 2025, then decreased by 8.08% to $6.9 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $6.9 billion in Q1 2026, $7.5 billion in Q4 2025, and $6.7 billion in Q3 2025.